Elan, Andrx Antitrust Battle Over Naproxen Deal Heads Back To District Court

Law360, New York (September 6, 2005, 12:00 AM EDT) -- A federal appeals court has reinstated part of an antitrust challenge to a deal between Irish drug maker Elan and Skyepharma over a generic version of the non-steroidal anti-inflammatory drug Naprelan (naproxen sodium).

The U.S. Court of Appeals for the 11th Circuit agreed with a Florida district court that the Noerr-Pennington doctrine immunized Elan from an antitrust suit based on generic maker Andrx’s allegations that Elan filed a sham lawsuit to protect its monopoly on the market for a controlled release naproxen medication.

However, the court...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.